Lv5
810 积分 2023-01-29 加入
An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL
1个月前
已关闭
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
3个月前
已完结
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
3个月前
已完结
Radiotheranostic landscape: A review of clinical and preclinical development
3个月前
已完结
Time-dependent lymphocyte count after transplantation is associated with higher risk of graft failure and death
4个月前
已完结
DAB389IL2 (ONTAK�) fusion protein therapy of chronic lymphocytic leukaemia
6个月前
已关闭
Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score
6个月前
已完结
The TCR/CD3 complex in leukemogenesis and as a therapeutic target in T-cell acute lymphoblastic leukemia
7个月前
已完结
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
7个月前
已完结
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide
7个月前
已完结
皖公网安备34019202002308
